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Abstract: In March 2010, a randomized trial called Pulmonary
Metastasectomy in Colorectal Cancer (PulMiCC) was launched and
is open to recruitment. The evidence for pulmonary metastasectomy
reviewed in this supplement includes no randomized trials. Claims
for a survival benefit for patients undergoing this surgery rely on
case series. Furthermore, there is little documentation of any
symptoms attributable to pulmonary metastases that are allevi-
ated or obviated by metastasectomy. The PulMiCC study aims
are to examine whether or not surgical resection of pulmonary
metastases from colorectal cancer lengthens survival and to
record systematically the harms and benefits of such surgery and
quality of life.
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In this supplement of the Journal of Thoracic Oncology thatreviews the evidence for the practice of pulmonary metas-
tasectomy, none of the authors have identified any random-
ized trials. Claims for a survival benefit for patients under-
going this surgery rely on case series. Furthermore, there is
little documentation of any symptoms attributable to pulmo-
nary metastases that are alleviated or obviated by metasta-
sectomy. In the particular instance of colorectal cancer, the
authors of the review explain the reasons for the perception of
benefit,1 but the evidence for cure, life extension, disease
modification, or palliation achieved by pulmonary metasta-
sectomy is not of a standard required in evidence-based
medicine.2,3
To address these shortcomings in the evidence base,
during 2010, a randomized trial called pulmonary metasta-
sectomy in colorectal cancer (PulMiCC) opened to recruit-
ment on March 17, 2010. The study was first proposed in the
BMJ in 2007,4 and further soundings were taken by publish-
ing the proposal in the European Journal of Surgical Oncol-
ogy.3 The study questions whether surgical resection of pul-
monary metastases from colorectal cancer lengthens survival
and whether surgery makes any difference (positive or neg-
ative) to symptoms and quality of life.
In this article, key elements of the PulMiCC trial are
described with the rationale for performing the study in the
context of the available evidence. It might not be applicable
to all pulmonary metastasectomy practices but merits consid-
eration. Trials of surgery within multimodality cancer treat-
ments are not easy but can be achieved.5
PATIENTS ELIGIBLE FOR THE PULMICC TRIAL
The criteria for pulmonary metastasectomy are in es-
sence those set out very clearly by Kondo et al.6—an update
of the well-known Thomford criteria.7
1. The patient must be a good risk for surgical interven-
tion.
2. The primary site is controlled.
3. No other metastatic disease; or, if present, it can be
controlled by surgery or another treatment modality.
4. Pulmonary metastases are thought to be completely
resectable.
In the context of the PulMiCC trial that is only recruit-
ing patients with colorectal cancer, the third criterion specif-
ically refers to liver metastasis.
Importantly, it should not be assumed that patients who
present with a solitary lung nodule against a background of
colorectal cancer necessarily have a colorectal pulmonary
metastasis. Every such nodule should be considered as a
matter for diagnosis and management in its own right, in case
it is a primary lung cancer or another pulmonary pathology.8
This should be done by the multidisciplinary team or cancer
board designated to deal with thoracic cancer in collaboration
with the colorectal team.
It is recognized that all teams performing pulmonary
metastasectomy for spread of colorectal cancer select cases
on the basis of features that can be identified before surgery.9
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Y There are patients in whom the question of pulmonary
metastasectomy is ruled out early on. Patients with a
large number of metastases appearing very soon after
the resection of an aggressive cancer with locoregional
nodal involvement and a high carcinoma embryonic
antigen (CEA) assay (for example) would be excluded.
Y There are patients in whom pulmonary metastasectomy
is undertaken by nearly all groups. Most teams would
remove the metastases if a patient had one or two
nodules, appearing after a long interval of approximately
3 to 4 years, which are growing but at a slower pace.
The important point to note is that if there is concor-
dance that at one end of the spectrum the team will vote “yes”
and at the other “no,” there must be a transition zone where
there is uncertainty sufficient to merit critical evaluation or
even to justify being called equipoise.
The most recently reported multivariable analysis is in
378 patients having pulmonary metastasectomy for colorectal
cancer at Memorial Sloane Kettering in a 10-year period from
1998.10 The authors found more than three metastases, a
longer interval between primary and metastasectomy surgery,
the stage of primary surgery, and the presence of extratho-
racic metastases, to be adverse prognostic factors. Of course,
these are prognostic factors related to cancer, but they are not
predictors of whether the operations work or not. The Me-
morial Sloane Kettering group also found female sex and age
younger than 65 years to be adverse prognostic features.
Probably, more informative than the p values are the hazard
ratios. Hazard ratios, with their 95% confidence intervals, are
0.68 (0.49–0.94) for male sex and 0.74 (0.54–1.01) for age
older than 65 years. These relative differences in the likeli-
hood of living 5 years depending on age and sex are hardly
evidence of the effectiveness of the surgery in curing cancer.
PulMiCC is pragmatic and deliberately sets no inclu-
sion or exclusion criteria for cancer-related factors, such as
number, size, CEA, the stage or differentiation of the primary
cancer, and the timing of the appearance of the metastases in
relation to the primary resection. Instead, we recognize that
between the group of patients for whom there is a confident
decision in favor of pulmonary metastasectomy and those
patients for whom there is a confident decision against, there
must be some for whom the team debates what to do for the
best. This is an expression of uncertainty. We contend that if
there is real clinical uncertainty among experts, randomized
allocation is as rational a management policy as following a
hunch. The situation is summarized in Table 1. Note that the
five criteria are presented without boundaries. There is no
cutoff for any of them. There are others that can be consid-
ered. The clinical decisions weigh these factors separately
and in combination.
Cancer teams interested in joining PulMiCC are re-
quested to reflect on their existing practice and to define their
“zone of uncertainty.” Table 2 shows how this exercise was
used to categorize a series of 45 patients who had undergone
pulmonary metastasectomy in the Northern General Hospital,
Sheffield, UK (with permission), whose practice is very much
in line with that in the many published case series.11
THE TRIAL DESIGN
We have learned a great deal about how this trial might
succeed from the Mesothelioma and Radical Surgery trial
into which, contrary to all predictions, randomization has
proved feasible.5,12 Following that model, we have designed
two stages to the consent process. However, to succeed in
running a trial, it is vital that the patients are told the truth
from the outset and introduced to the concept of uncertainty
about the best course of action for them in a neutral way. At
present, all too often, a well-meaning nurse or oncologist
breaks the news to them and proposes their own solution:
“The scans show recurrence of your cancer in the form of
little nodules in your lungs, but don’t worry—we’ll send you
to the thoracic surgeon to take them out.” Thoracic surgeons
are very familiar with this scenario, turning the patient down
for surgery after such an introduction conveys the message of
“giving up,” or worse, administering a death sentence by
inaction.
We hope to pre-empt expectations of a surgical inter-
vention in the minds of patients by providing them with not
only the standard patient information sheet but also a pur-
pose-made explanatory digital video disc. This digital video
disc (DVD) supplements the patient information sheet and
includes cartoons of the logic and purpose of randomization,
schematic diagrams and explanations about different types of
TABLE 1. Factors That Can be Established Before Surgery
Are Known from One or More Multivariable Analysis to be
Associated with Survival and Are Commonly Taken into
Account in the Selection of Patients for Pulmonary
Metastasectomy in Colorectal Cancer
Factor
Favors
Surgery
Weighs Against
Surgery
Time since primary
surgery (yr)
3 No interval or less than
a year
CEA Not raised Markedly raised
Number of metastases 1–3 Many
Liver metastases 0–1 Multiple
Primary stage T1–2 N0 M0 T3–4 N1–2 M1
CEA, carcinoma embryonic antigen.
TABLE 2. A Consecutive Series of 45 Patients Undergoing
Pulmonary Metastasectomy for Colorectal Cancer in the
Northern General Hospital, Sheffield, UK
Factor Favorable N N Adverse N Unknown
Time since
primary
surgery (yr)
3 17 1–3 12 12 1 5
CEA (ng/ml) 5 15 5–10 8 10 3 19
Number of
metastases
1 39 2–5 6 5 0 0
Liver metastases None 31 Resected 14 Present 0 0
The predominance of single metastasectomy, low CEA, and long intervals is in line
with reported series. It may be that the team would not wish to randomize future patients
such as these but might have uncertainty about less “favorable” patients and would offer
the trial.
CEA, carcinoma embryonic antigen.
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surgery, and clips of real doctors answering typical patients’
queries. At trial launch, the centers participating in PulMiCC
also have an interactive communication skills training session
that aims to assist all involved in providing even-handed
descriptions of the patients’ options including trial entry.
Ethical Considerations
At this point, the question of ethics will come to many
readers’ minds, and quite rightly. Two ethicists are included
in the trial development group: one from legal background
and the other a professor of philosophy. The position of the
PulMiCC investigators is that if one could trade relative
ethics, it is more ethical to come clean and tell the patient that
there is uncertainty about whether metastasectomy will cure
them rather than to encourage the unproven belief that it will.
It is more ethical to find evidence than to perform surgery that
is not evidence based. For a more detailed consideration of
research ethic and randomization, read the essay by Martyn
Evans,13 the philosopher in our trial development group.
First Consent
At first consent, patients agree to enter the PulMiCC
study. They may have probable or confirmed pulmonary
metastases and during this phase of the study will have any
further investigations required to evaluate the lung nodules
that have been identified. The work-up is no more than what
is required to meet the updated Thomford criteria.7 In most
cases, this will include positron emission tomography
(mainly to reduce the chance of missing unsuspected
disease at other sites) as well as computed tomography
scans. Control at the primary site will be confirmed by the
colorectal cancer team. Tissue diagnosis will be obtained if
there is clinical doubt about the nature of the pulmonary
nodule(s). If chemotherapy is judged appropriate, it can be
given during this phase of the study.
The question of liver metastases frequently arises. The
incidence of metastatic disease increased from 15% in 1970s
to 22% since 2000, based on 34 studies including 2356
patients’ records.11 There were about a third in the Sheffield
series and 38% in the MSK series.10 PulMiCC asks that if
these are considered suitable for resection, this surgery
should be performed and they will then be reconsidered.
After this process, some patients will be deemed un-
suitable for pulmonary metastasectomy; in some cases, the
team will want to offer surgery because they see the patient as
matching their existing criteria. These patients will be man-
aged, as agreed between them and their clinicians, but their
data will be retained. Patients for whom pulmonary metasta-
sectomy is an option, but for whom there is uncertainty, will
be offered randomization within PulMiCC.
Second Consent
Patients consent to be allocated to continued active
monitoring or to pulmonary metastasectomy and continued
active monitoring. The allocation will be performed offsite
and will use minimization in addition to an element of
random allocation. Minimization is a means of ensuring
balance between the groups for confounding factors, such as
the number of metastases, the interval since the primary
resection, the CEA, the T and N stage of the colorectal
cancer, history of liver metastases, age, and sex. This ap-
proach is well established and is particularly valuable where
there is heterogeneity and the trial is relatively small.14,15
Pulmonary Metastasectomy
Reviewers of the literature in this supplement and
elsewhere16–19 have been unable to make evidence-based
recommendations for whether surgery should be by mini-
mally invasive video surgery or open, unilateral or bilateral,
or what surgical technique should be used. We know that
practice varies widely.20 There would be no rational basis to
do other than to allow these matters to be determined by local
preferred practice and what is most appropriate for the indi-
vidual patient.
Radiofrequency ablation seems to be growing in pop-
ularity21 and may be more used in future.22 However, it fails
to meet the criteria for the management of metastasectomy in
that there is no way of confirming an R0 resection. It also
precludes proving that the lesion was a metastasis, and not
every metastasis needs to be histologically confirmed before
metastasectomy. It may well be that there will be slippage in
this direction, but patients are free to seek treatment outside
the trial, and PulMiCC trialists recognize that some clinicians
will want to do something active for their patients.
Outcome
Survival is the primary outcome measure. It is essential
that the quality of survival is better known than at present,
whether there are gains or losses associated with pulmonary
metastasectomy. On the positive side, some believe that
removal of metastases pre-empts the development of symp-
toms, so if the operation is not curative, it is still palliative.
On the downside there is the inevitable pain of thoracotomy
and, with larger resections, loss of lung function, so respira-
tory function will be measured regularly. Patients may also
find the inconvenience of hospitalization impacts on quality
of life while those who have only active monitoring may
experience more anxiety. Standardized patient-reported out-
come measures will be used to assess these issues 3, 6, 12,
and 24 months after surgery.
Y Functional Assessment of Cancer Therapy—General
(FACT-G) and FACT anemia/fatigue subscale (FACT-
An) plus selected items from the FACT Lung Cancer
Brief Symptom Index.
Y Short form of the Spielberger State/Trait Anxiety
Inventory.
The health economic implications of pursuing different
management policies will also be evaluated via the EQ-5D
questionnaire administered at similar time points to the ques-
tionnaires listed previously.
DISCUSSION
Do We Need a Randomized Trial Anyway?
Nearly all surgeries have developed from practical
solutions to evident problems. We do not need randomized
trials to know that the lame walk better after hip replacement
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and the blind recover their sight after cataract surgery. The
results would have been seen as miraculous in biblical
terms.23 There are many instances in surgery from the Tho-
mas’s splint for femoral fracture to aortic valve replacement
for stenosis, where the benefit attributable to surgery is
immediate and irrefutable. This form of evidence is accepted
and well defined by evidence-based medicine experts.24,25
However, this is not applicable in all circumstances. The
retrospective analysis of surgical series, which is the form of
evidence offered in favor of pulmonary metastasectomy, has
many pitfalls.26
The paucity of randomized trials in surgery prompted a
now classic editorial in The Lancet, comparing surgeons’
efforts in research with “comic opera,”27 but still they are
commonly rejected as being too difficult, a view that has been
countered elsewhere.28 Our view is that the highly selected
nature of patients undergoing pulmonary metastasectomy, the
great variation in the clinical course of different patients with
cancer, and the use of combinations of therapies make it
impossible to discern the effect of surgery on survival; we
cannot see the signal from the noise in this instance,24 and so
we developed PulMiCC.
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